Answers are grounded in this paper and cite their sources.
Stroke poses a severe threat to human health, with limited therapeutic options currently available. Astragaloside IV (AS-IV), a primary bioactive metabolite derived from Astragalus membranaceus, exhibits multifaceted pharmacological effects, including anti-inflammatory, anti-fibrotic, and antioxidative properties. This review systematically examines recent advances in AS-IV research for stroke treatment, detailing its sources, physicochemical characteristics, mechanisms of action, and therapeutic efficacy in both in vitro and in vivo models. We critically analyze the potential of AS-IV as an adjunctive therapy for stroke, addressing current research hotspots, challenges, and emerging strategies. Notably, AS-IV synergistically enhances neuroprotection when combined with other plant-derived metabolites. This work provides a theoretical foundation for further development of AS-IV in stroke management. In summary, AS-IV demonstrates significant promise as a natural neuroprotective agent worthy of continued exploration for adjuvant stroke therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: